Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Grants
  • About Akademiliv

Study paves the way for precision treatment of type 2 diabetes

24 January, 2024

NEW STUDY. GLP1 medicines work best for those diabetes patients who have a reduced production of insulin. The study from the University of Gothenburg shows that it is possible to personalize the treatment of type 2 diabetes.

This is the first clinical study to systematically test whether personalizing medical treatment of type 2 diabetes can work, and how such personalization could work in the healthcare practice. The results of the study are published in the journal Nature Metabolism.

The study used the two most cutting-edge diabetes medicines, GLP1 medicines and SGLT2 inhibitors. The study recruited 239 participants from two different subgroups of type 2 diabetes. The results show that GLP1 medicines are significantly more effective in patients where the underlying disease mechanism is impaired insulin production. For patients with lower BMI and high insulin production, the SGLT2 inhibitor worked well, but for 30% of the patients in the study, SGLT2 inhibitors were found to have no effect at all.

Low insulin production or high resistance

Anders Rosengren. Photo: Johan Wingborg.

The work has been led by Anders Rosengren, a professor at the Institute of Neuroscience and Physiology, who is also affiliated with the Wallenberg Centre for Molecular and Translational Medicine (WCMTM) at the University of Gothenburg.

“The two medicinal products have different mechanisms of action, and there is a wide variation in how patients respond to them. Therefore, there may be an advantage in personalizing the treatment, but so far there have been no randomized studies in this area,” says Anders Rosengren.

“We started from a recent discovery in a Swedish collaboration, where we showed that type 2 diabetes can be divided into several subgroups, based on different disease characteristics and risks of complications. The two subgroups included in the study are the two most severe, where one has low insulin production and the other has good insulin production but high insulin resistance,” says Anders Rosengren.

Tailored treatment

In the study, patients were randomly assigned to one of two diabetes groups, with half receiving GLP1 medicines and the other half receiving SGLT2 inhibitors.

“In total, we had four different study groups with over fifty diabetic patients in each group. They were randomized to one of the medicines for six months, and we followed the effect on their long-term blood sugar,” says Anders Rosengren and continues:

“Since the group with low insulin production had a significantly better response to GLP1 medicines compared to those whose disease is due to high insulin resistance, this opens up the possibility of tailoring treatment according to the patient’s subgroup.”

Several factors come into play

Semaglutide Ozempic can be administrated as an injection. Genre image by Getty Images.

However, sorting patients into subgroups can be too rigid a tool, according to Anders Rosengren. The study shows that the personalization of diabetes treatment can be even more effective by considering data on insulin secretion, insulin resistance, blood pressure and weight for each patient.

“Today, doctors try to find the treatment that works best for the patient, but this presents an opportunity to provide the most effective treatment adapted to the individual disease situation right from the start,” says Anders Rosengren.

Improperly treated diabetes can increase the risk of several serious complications, especially for certain subgroups. “The relatively inexpensive C-peptide test could help doctors determine more precisely which medicine a patient should receive for best effect,” says Anders Rosengren:

“It is a simple fasting test for insulin production that is already available in healthcare centers. It would not be difficult to introduce it into clinical practice, providing a valuable tool to improve the clinical management of patients.”

Title: Dwibedi C et al., Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology; Nature Metabolism 2024; https://doi.org/10.1038/s42255-023-00943-3.

BY: ELIN LINDSTRÖM

 

 

 

 

By: Elin Lindström
Tagged With: institutionen för neurovetenskap och fysiologi, Ny studie, vetenskaplig publicering

HAPPY SUMMER!

The newsletter from Akademiliv will return on Wednesday, August 21st.

Contact your institute to add your event to the calendar in the Staff Portal

  • Biomedicine: Kristian Kvint: kalender@biomedicine.gu.se
  • Core Facilities: Amelie Karlsson: amelie.karlsson.2@gu.se
  • Clinical Sciences: Katarina Olinder Eriksson: klinvet@gu.se
  • Medicine: Nina Raun; kommunikation@medicine.gu.se
  • Neuroscience and Physiology: Josefin Bergenholtz; kommunikation@neuro.gu.se
  • Odontology: Johan Thompson; info@odontologi.gu.se
  • Sahlgrenska Academy’s Office and faculty-wide calendar events Åsa Ekvall; info@sahlgrenska.gu.se
  • Health and Care Sciences: Karin Mossberg; vardvetenskap@fhs.gu.se

Information from Sahlgrenska Academy Research Support Office

[UPDATED JUNE 2024]
The Sahlgrenska Academy Research Support Office provides an overview of upcoming and current calls, nominations and events in an information letter. This letter is updated on a monthly basis.
Current and previous newsletters are also available in the Staff Portal.

’20 minutes for researchers’ is back – see full spring program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life.

More news

En personlig död (A Personal Death) – a chance to win Björn Fagerberg’s new book

27 May, 2024

NEW BOOK. During his career as a physician specializing in internal medicine, Björn Fagerberg has been involved in many end-of-life situations, …  

She is doing her residency in the US with a medical degree from Gothenburg

21 May, 2024

STUDENT. Doing a “residency” in orthopedics in the United States is an unattainable dream for many newly qualified American doctors. Now Janina Ka …  

Alba Corell reports from a high-level brain tumor meeting

20 May, 2024

COLUMN. The recent gathering of the Scandinavian Society of Neuro-oncology (SNOG) in Gothenburg has concluded. Professor Asgeir Jakola hosted and …  

From South Africa to Sweden: Collaborative Research Efforts Improving Pregnant Women’s Health

17 May, 2024

GLOBAL HEALTH. In the bustling Tygerberg University Hospital in Cape Town, a dedicated research team led by Lina Bergman, is on a mission to …  

Sara Bjursten and Anna Wenger are the recipients of the Assar Gabrielsson Prize 2024

17 May, 2024

AWARD. The Assar Gabrielsson Foundation has named Anna Wenger as the winner in the basic science research category and Sara Bjursten as the …  

A full day for PhD students focused on mental health

16 May, 2024

PHD STUDENTS. For the sixth time, PhD students at Sahlgrenska Academy were invited to PhD Day, organized by the Doctoral Student Council. The day …  

Kaj Blennow ranked highest in Sweden in neuroscience

16 May, 2024

AWARD. In this year's edition of the researcher ranking from Research.com in the field of neuroscience, Kaj Blennow is ranked 17th …  

Linda Wass is doing a postdoc at Stanford with ALF funding

14 May, 2024

ALF FUNDING. Biomedical Scientist Linda Wass has just settled in Stanford, California, where she will spend two years as a postdoc. She is the …  

Karin Nilsson wrote the Thesis of the Year at Sahlgrenska Academy in 2023

14 May, 2024

AWARD. Karin Nilsson, currently a postdoc at the Department of Internal Medicine and Clinical Nutrition, receives the faculty-wide Thesis of the …  

Some answers from the proposed members of the next Faculty Board

14 May, 2024

FACULTY ELECTIONS. The eight proposed members of the next Faculty Board hereby give some brief answers on how they want to contribute to the work …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen